A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,437,073 shares of RCUS stock, worth $38.9 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
2,437,073
Previous 1,833,851 32.89%
Holding current value
$38.9 Million
Previous $27.9 Million 33.42%
% of portfolio
0.1%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $8.26 Million - $10.9 Million
603,222 Added 32.89%
2,437,073 $37.3 Million
Q2 2024

Aug 14, 2024

SELL
$14.59 - $18.48 $1.18 Million - $1.5 Million
-81,081 Reduced 4.23%
1,833,851 $27.9 Million
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $17 Million - $23.1 Million
1,146,182 Added 149.1%
1,914,932 $36.2 Million
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $10.3 Million - $15 Million
764,293 Added 17148.15%
768,750 $14.7 Million
Q3 2023

Nov 14, 2023

SELL
$17.62 - $23.54 $12.4 Million - $16.6 Million
-705,184 Reduced 99.37%
4,457 $80,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $12 Million - $15.6 Million
709,641 New
709,641 $14.4 Million
Q1 2023

May 15, 2023

SELL
$15.96 - $23.15 $6.79 Million - $9.85 Million
-425,301 Closed
0 $0
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $7.24 Million - $13.1 Million
367,467 Added 635.38%
425,301 $8.8 Million
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $1.34 Million - $1.74 Million
57,834 New
57,834 $1.51 Million
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $1.43 Million - $2.25 Million
-62,926 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $1.65 Million - $2.6 Million
62,926 New
62,926 $1.77 Million
Q4 2020

Feb 16, 2021

SELL
$17.0 - $32.36 $3.3 Million - $6.28 Million
-194,001 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$17.14 - $25.47 $3.33 Million - $4.94 Million
194,001 New
194,001 $3.33 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.